NR3C1 (nuclear receptor subfamily 3, group C, member 1/glucocorticoid receptor)

Show full item record

Files in this item

PDF 02-2015-NR3C1ID45665ch5q31.pdf 405.9Kb

Pour citer ce document :
URI:  |   DOI :
Title: NR3C1 (nuclear receptor subfamily 3, group C, member 1/glucocorticoid receptor)
Author: Siamatras, Thomas D; Stratakis, Constantine A
Abstract: NR3C1 gene encodes the human glucocorticoid receptor(hGR), which is a ligand-dependent transcription factor and activates transcription of glucocorticoid-responsive genes through binding directly to glucocorticoid response elements(GREs) in their promoter region, or modulating transcriptional activity of other transcription factors through protein-protein interactions. hGR is implicated in a broad spectrum of biochemical physiologic functions, which are essential for life, and has also a key role in the maintenance of basal and stress-related homeostasis. Almost 20% of the genes expressed in human leukocytes are regulated positively or negatively by the hGR. Approximately every cellular, molecular and other physiologic network in the human body are influenced by this receptor and more specifically growth, reproduction, intermediary metabolism, immune and inflammatory reactions, as well as central nervous system and cardiovascular functions and lymphoproliferative disorders, cellular proliferation and differentiation in target tissues and normal renal tubular function and thus water and electrolyte homeostasis are only some of the examples where hGR is implicated(Nicolaides, Galata, Kino, Chrousos, and Charmandari, 2010).
Subject: Genes Section; Apoptosis/*drug effects; Boronic Acids/therapeutic use/toxicity; Bortezomib; Cell Line, Tumor; Dexamethasone/toxicity; Dimerization; Drug Synergism; Hematologic Neoplasms/drug therapy/metabolism/pathology; Humans; K562 Cells; Lymphoma/drug therapy/metabolism/pathology; NF-kappa B/antagonists & inhibitors/metabolism; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug; Proteasome Inhibitors/therapeutic use/*toxicity; Pyrazines/therapeutic use/toxicity; RNA Interference; RNA, Small Interferi
Publisher: Jean-Loup Huret (Editor-in-Chief)
Date: 2016

This item appears in the following Collection(s)

Show full item record

Advanced Search